In vivo zebrafish assays for toxicity testing

Area of Science:

• Pharmacology and Toxicology
• Developmental Biology
• Drug Discovery

Background:

• Drug development frequently fails due to unforeseen in vivo toxicity, despite promising cell culture results.
• Assessing absorption, distribution, metabolism, and excretion (ADME)-related toxicity early is crucial to minimize late-stage failures.
• Current methods involve costly and time-consuming animal testing, necessitating more efficient screening approaches.

Purpose of the Study:

• To highlight the utility of zebrafish as an intermediate model for in vivo toxicity screening.
• To demonstrate how zebrafish assays can bridge the gap between cell-based and mammalian toxicity testing.
• To advocate for the integration of zebrafish toxicity assays into early drug development pipelines.

Main Methods:

• Utilizing the transparent zebrafish model for direct visualization of internal organs, tissues, and cells.
• Implementing straightforward in vivo assays for toxicity assessment.
• Comparing zebrafish assay outcomes with traditional cell-based and later-stage mammalian studies.

Main Results:

• Zebrafish offer unparalleled accessibility for observing in vivo toxicological effects.
• Zebrafish assays provide a reliable intermediate step for predicting in vivo toxicity.
• This approach effectively reduces the need for extensive late-stage animal testing.

Conclusions:

• Zebrafish are a valuable model organism for early-stage in vivo toxicity screening in drug discovery.
• Integrating zebrafish assays streamlines the drug development process, saving time and resources.
• Early toxicity assessment in zebrafish can significantly improve the success rate of drug candidates.